Production of pure indinavir free base nanoparticles by a supercritical anti-solvent (SAS) method

References

• UNAIDS report on the global AIDS epidemic, Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf [last accessed 28 April 2013]
   Google Scholar
• Panel of clinical practices for treatment of HIV infection. Pan Am J Public Health 2001;10:426–35
   Google Scholar
• Delaney M. History of HAART – the true story of how effective multi-drug therapy was developed for treatment of HIV disease. Retrovirology 2006;3:S6
   PubMed Web of Science ®Google Scholar
• Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009;323:1304–7
   PubMed Web of Science ®Google Scholar
• Romanelli F, Hoven AD. Use of virostatics as a means of targeting human immunodeficiency virus infection. Curr Pharm Des 2006;12:1121–7
   PubMed Web of Science ®Google Scholar
• Geeraert L, Kraus G, Pomerantz RJ. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 2008;59:487–501
   PubMed Web of Science ®Google Scholar
• Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281–92
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22:11–23
   PubMed Web of Science ®Google Scholar
• Ruela Corrêa JC, D’Arcy DM, dos Reis Serra CH, Nunes Salgado HR. Darunavir: a critical review of its properties, use and drug interactions. Pharmacology 2012;90:102–9
   PubMed Web of Science ®Google Scholar
• Lin JH. Role of pharmacokinetics in the discovery and development of indinavir. Adv Drug Deliv Rev 1999;39:33–49
   PubMed Web of Science ®Google Scholar
• Johnson BD, Howard A, Varsolona R, et al. Indinavir sulfate. In: Brittain HG, ed. Analytical profiles of drug, substances and excipients. Vol. 26. San Diego: Academic Press; 1999:319–57
   Google Scholar
• de Carvalho e Silva B, Moreira de Campos LM, Pianetti GA. Development and validation of an alternative titration method for the determination of sulfate ion in indinavir sulfate. Quím Nova 2005;28:54–6
   Web of Science ®Google Scholar
• Singh P, Premkumar L, Mehrotra R, et al. Evaluation of thermal stability of indinavir sulphate using diffuse reflectance infrared spectroscopy. J Pharmaceutical Biomed Anal 2008;47:248–54
   PubMed Web of Science ®Google Scholar
• Ferreira da Silva RM, Morais de Medeiros FP, Nascimento TG, et al. Thermal characterization of indinavir sulfate using TG, DSC and DSC-photovisual. J Thermal Anal Calorim 2009;95:965–8
   Web of Science ®Google Scholar
• Yeh KC, Deutsch PJ, Haddix H, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998;42:332–8
   PubMed Web of Science ®Google Scholar
• Arribas JR, Doroana M, Turner D, et al. on behalf of the panel members. Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting. AIDS Res Ther 2013;10:Art. 3
   Google Scholar
• Boyd M. Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role? Expert Opin Pharmacother 2007;8:957–64
   PubMed Web of Science ®Google Scholar
• Salahuddin S, Kok DJ, Buchholz NN. Influence of body temperature on indinavir crystallization under loop of Henle conditions. J Antimicrobial Chemother 2007;59:114–17
   PubMed Web of Science ®Google Scholar
• Prezista, European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000707/WC500041754.pdf [last accessed 13 Aug 2013]
   Google Scholar
• das Neves J, Amiji MM, Bahia MF, Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Del Rev 2010;62:458–77
   PubMed Web of Science ®Google Scholar
• Gupta U, Jain NK. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Del Rev 2010;62:478–90
   PubMed Web of Science ®Google Scholar
• Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004;3:785–96
   PubMed Web of Science ®Google Scholar
• Müller RH, Gohla S, Keck CM. State of the art of nanocrystals – special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm 2011;78:1–9
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 2008;36:43–8
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Del Rev 2007;59:631–44
   PubMed Web of Science ®Google Scholar
• Williart JF, Descamps M. Solid state amorphization of pharmaceuticals. Mol Pharmaceutics 2008;5:905–20
   PubMed Web of Science ®Google Scholar
• Naylor A, Lewis AL, Illum L. Supercritical fluid-mediated methods to encapsulate drugs: recent advances and new opportunities. Ther Deliv 2011;2:1551–65
   PubMedGoogle Scholar
• Pasquali I, Bettini R, Giordano F. Solid-state chemistry and particle engineering with supercritical fluids in pharmaceutics. Eur J Pharm Sci 2006;27:299–310
   PubMed Web of Science ®Google Scholar
• Charbit G, Badens E, Boutin O. Methods of particle production. In: York P, Kompella UB, Shekunov BY, eds. Supercritical fluid technology for drug product development (drugs and the pharmaceutical sciences). Vol. 138. New York: Marcel Dekker, Inc. 2004:159--212
   Google Scholar
• Fages J, Lochard H, Letourneau JJ, et al. Particle generation for pharmaceutical applications using supercritical fluid technology. Powder Technol 2004;141:219–26
   Web of Science ®Google Scholar
• Yeo SD, Kim MS, Lee JC. Recrystallization of sulfathiazole and chlorpropamide using the supercritical fluid antisolvent process. J Supercrit Fluid 2003;25:143–54
   Web of Science ®Google Scholar
• Rehman M, Shekunov BY, York P, Colthorpe P. Solubility and precipitation of nicotinic acid in supercritical carbon dioxide. J Pharm Sci 2001;90:1570–82
   PubMed Web of Science ®Google Scholar
• Toteva MM, Zanon R, Ostovic D. Kinetics and mechanism of the hydrolytic degradation of indinavir: intramolecular catalysis. J Pharm Sci 2008;97:3810–19
   PubMed Web of Science ®Google Scholar
• Sacchetin PSC, Morales AR, Moraes AM, Rosa PTV. Formation of PLA particles incorporating 17α-methyltestosterone by supercritical fluid technology. J Supercrit Fluid 2013;77:52–62
   Web of Science ®Google Scholar
• Liu H, Pierre-Pierre N, Huo Q. Dynamic light scattering for gold nanorod size characterization and study of nanorod–protein interactions. Gold Bull 2012;45:187–95
   Web of Science ®Google Scholar
• Van der Zande BMI, Dhont JKG, Bohmer MR, Philipse AP. Colloidal dispersions of gold rods characterized by dynamic light scattering and electrophoresis. Langmuir 2000;16:459–64
   Web of Science ®Google Scholar
• Lehner D, Lindner H, Glatter O. Determination of the translational and rotational diffusion coefficient of rodlike particles using depolarized dynamic light scattering. Langmuir 2000;16:1689–95
   Web of Science ®Google Scholar
• Hochman JH, Chiba M, Nishime J, et al. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther 2000;292:310–18
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3–26
   PubMed Web of Science ®Google Scholar
• Imperiale JC, Chiappetta DA, Sosnik A. Novel mucoadhesive nano-drug delivery system for the sustained delivery of protease inhibitors in the treatment of HIV. OBI 2011-2nd Workshop on biomaterials, artificial organs and tissue engineering; 2011 Sep 28–30, Mar del Plata, Argentina
   Google Scholar
• Andujar P, Lanone S, Brochard P, Boczowski J. Respiratory effects of manufactured nanoparticles. Rev Maladies Resp 2011;28:e66–75
   PubMedGoogle Scholar
• de Marco I, Reverchon E. Influence of pressure, temperature and concentration on the mechanisms of particle precipitation in supercritical antisolvent micronization. J Supercrit Fluid 2011;58:295–302
   Web of Science ®Google Scholar
• Yang L, Sun Z, Zu Y, et al. Physicochemical properties and oral bioavailability of ursolic acid nanoparticles using supercritical anti-solvent (SAS) process. Food Chem 2012;132:319–25
   PubMed Web of Science ®Google Scholar
• Dowy S, Braeuer A, Reinhold-López K, Leipertz A. In situ optical monitoring of the solution concentration influence on supercritical particle precipitation. J Supercrit Fluid 2010;55:282–91
   Web of Science ®Google Scholar
• Braeuer A, Dowy S, Torino E, et al. Analysis of the supercritical antisolvent mechanisms governing particles precipitation and morphology by in situ laser scattering techniques. Chem Eng J 2011;173:258–66
   Web of Science ®Google Scholar
• Kalani M, Yunus R. Application of supercritical antisolvent method in drug encapsulation: a review. Int J Nanomed 2011;6:1429–42
   PubMed Web of Science ®Google Scholar
• Sui X, Wei W, Yang L, et al. Preparation, characterization and in vivo assessment of the bioavailability of glycyrrhizic acid microparticles by supercritical anti-solvent process. Int J Pharm 2012;423:471–9
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997;49:403–49
   PubMed Web of Science ®Google Scholar
• Phillips DJ, Pygall SR, Cooper VB, Mann JC. Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems. J Pharm Pharmacol 2012;64:1549–59
   PubMed Web of Science ®Google Scholar
• Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999;186:119–25
   PubMed Web of Science ®Google Scholar
• Yu LX, Crison JR, Amidon GL. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm 1996;140:111–18
   Web of Science ®Google Scholar
• Sosnik A, Chiappetta DA, Carcaboso A. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. J Control Release 2009;138:2–15
   PubMed Web of Science ®Google Scholar
• Chiappetta DA, Carcaboso AM, Bregni C, et al. Indinavir-loaded ph-sensitive microparticles for taste masking: towards extemporaneous paediatric HIV/AIDS liquid formulations with improved patient compliance. AAPS PharmSciTech 2006;10:1–6
   Web of Science ®Google Scholar
• Sosnik A. Nanotechnology contributions to the pharmacotherapy of pediatric HIV: a dual scientific and ethical challenge and a still pending agenda. Nanomedicine (Lond.) 2010;5:833–7
   PubMed Web of Science ®Google Scholar
• Sosnik A, Amiji M. Nanotechnology solutions for infectious diseases in developing nations. Adv Drug Del Rev 2010;62:375–7
   PubMed Web of Science ®Google Scholar
• Sosnik A, Seremeta KP, Imperiale JC, Chiappetta DA. Novel formulation and drug delivery strategies for the treatment of pediatric poverty related diseases (PRDs). Expert Op Drug Deliv 2012;9:303–23
   PubMed Web of Science ®Google Scholar
• Imperiale JC, Sosnik A. Nanoparticle-in-microparticle delivery systems (NiMDS): production, routes of administration and clinical potential. J Biomater Tissue Eng 2013;3:22–38
   Google Scholar
• Imperiale JC. Microencapsulation processes of protease inhibitors for the optimization of the pharmacotherapy of the Human Immunodeficiency Virus (HIV) [PhD Thesis]. Faculty of Pharmacy and Biochemistry, University of Buenos Aires; 2013
   Google Scholar